

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q91145

Shinichiro KITAHARA, et al.

Appln. No.: 10/555,069

Group Art Unit: Not Yet Assigned

Confirmation No.: Not Yet Assigned

Examiner: Not Yet Assigned

Filed: October 28, 2005

For:

INSTRUMENT FOR INDUCING CYTOKINE AND METHOD OF INDUCING

CYTOKINE

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicants hereby notify the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after INFORMATION DISCLOSURE STATEMENT

U.S. Appln. No.: 110/555069

Attorney Docket No. Q91145

filing a request for continued examination (RCE) under §1.114, and therefore, no Statement

under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such

document constitutes prior art against the claims of the present application. Applicant does not

waive any right to take any action that would be appropriate to antedate or otherwise remove any

listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue

Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any

overpayments to said Deposit Account.

Respectfully submitted,

Registration No. 30,951

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: March 24, 2005

2

				14		MODIFIED F10/35/08 A & B (00-03		
Subs	Substitute for Form 1449 A & B/PTO				Complete if Known			
					Application Number	10/555,069		
ALE	INTUI	RMATION I	DISCLOS	SURE	Confirmation Number	Not Yet Assigned		
STATEMENT BY APPLICANT					Filing Date	October 28, 2005		
					First Named Inventor	Shinichiro KITAHARA		
NY Sa	1 2006 (use	as many sheets	as necessa	ry)	Art Unit	Not Yet Assigned		
	<i>\\$</i> /				Examiner Name	Not Yet Assigned		
×	heet	1	of	1	Attorney Docket Number	Q91145		

U.S. PATENT DOCUMENTS								
Examiner	Cite No.1	Document	Number	Publication Date				
Initials*		Number	Kind Code ² (if known)	MM-DD-YYYY	Name of Patentee or Applicant of Cited Document			
		US						
		US						
ĺ		US						
		US						
		US						
		US						
		US						
		US						
		US						

FOREIGN PATENT DOCUMENTS							
Examiner	Cite No.1	Foreign Patent Document			Publication Date	Name of Patentee or	
Initials*		Country Code ³	Number ⁴	Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation ⁶
		<u> </u>					

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*						
		All About Cytokines; Clinical Immunology, February 1995, pp. 1-7, 8-17, 250-258, 259-285, and 286-296, Vol. 27, Supp. 16.				
		KASAKURA, S., Novel Interleukins (IL-19, IL-20, IL-21), Clinical Immunity; 2001; pages 39-44; Vol. 36.				
		KASAKURA, S., IL-22 - IL-27, Clinical Immunity; 2003; pages 189-200; Vol. 39.				
		YAMADA et al.; Studies on Antitumor Mechanism of Biological Response Modifier (BRM) and Significance of Responder Evaluated by Cytokine Production II, Analysis on Cytokine Production Stimulated by BRMs Using Peripheral Blood; Gifu University Medical Report; 1995; 43:166-177.	Abstract and Partial Translation			
		HAYASHI, A., A New Trend of Cancer Immunotherapy: BCG-CWS as a Bridge Between the Innate Immunity and the Acquired, Molecular Medicine, 1999; 220-229; extra edition, Vol. 36.	Partial Translation -			

		1	
	ł		
Examiner Signature		Date Considered	
Examiner dignature	 I.	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.